Ben Woolven
Consultant / Advisor chez Resolution Therapeutics Ltd.
Profil
Ben joined Syncona from GlaxoSmithKline where he has over a decade of strategy development, business operations and project management experience.
Latterly Ben worked with GlaxoSmithKline’s Chief Medical Officer, where he led reconfiguration of global and regional medical functions in anticipation of their evolving pharma portfolio.
Prior to this, Ben held various strategy and operations roles building scientific teams, developing justifications for new scientific investments, leading project management offices and providing R&D consultancy support, including a secondment to L.E.K Consulting.
Prior to joining GlaxoSmithKline Ben played a key role in the success of Domantis, an antibody fragment start-up, sold to GlaxoSmithKline for £230 million.
Ben holds a PhD in Immunology.
Postes actifs de Ben Woolven
| Sociétés | Poste | Début |
|---|---|---|
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Consultant / Advisor | 01/02/2022 |
Anciens postes connus de Ben Woolven
| Sociétés | Poste | Fin |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01/11/2022 |
| GSK PLC | Directeur/Membre du Conseil | 01/02/2022 |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Corporate Officer/Principal | 01/02/2009 |
Formation de Ben Woolven
| University of Cambridge | Undergraduate Degree |
| University of Kent | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Commercial Services |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
